eMedicine Specialties > Pediatrics: General Medicine > Infectious Disease

Aspergillosis: Differential Diagnoses & Workup

Author: Vandana Batra, MD, Pediatrician, Department of Pediatrics, Division of General Pediatrics/Primary Care, Nemours Pediatrics
Coauthor(s): Basim Asmar, MD, Director, Department of Pediatrics, Division of Infectious Diseases, Children's Hospital of Michigan; Professor, Department of Pediatrics, Wayne State University School of Medicine; Jocelyn Y Ang, MD, Assistant Professor, Department of Pediatrics, Division of Infectious Diseases, Children's Hospital of Michigan and Wayne State University
Contributor Information and Disclosures

Updated: Oct 17, 2008

Differential Diagnoses

Allergic Rhinitis
Infections After Bone Marrow Transplantation
Asthma
Mucormycosis
Blastomycosis
Nocardiosis
Coccidioidomycosis
Paragonimiasis
Cystic Fibrosis
Fever Without a Focus
Histoplasmosis

Other Problems to Be Considered

  • Sinusitis: Evaluate patients whose chronic sinusitis does not respond to broad-spectrum antibacterial antibiotics for the possibility of invasive aspergillosis (IA).
  • Infection in patients with granulocytopenia: Consider aspergillosis in patients with granulocytopenia who develop signs and symptoms of infection.

Workup

Laboratory Studies

Laboratory studies in patients with aspergillosis include the following:

  • Microscopic examination and culture
    • The most common and definitive methods for the diagnosis of aspergillosis are direct microscopic examination and isolation of organism by culture; whenever possible, use both approaches because combining these techniques increases the yield by 15-20% over culture alone.
    • Microscopic examination of potassium hydroxide wet preparations or Gomori methenamine silver histopathological stains provide presumptive evidence of aspergillosis if they reveal dichotomously branched and septate hyphae. Stains such as calcofluor white may increase the sensitivity for microscopy.
    • Other fungi, such as Pseudallescheria boydii and Scopulariopsis species may appear similar to Aspergillus species under microscopy and may be mistaken for aspergillosis. Hence, definitive diagnosis relies on isolating the organism from culture media. Aspergillus can be isolated from culture of specimens (eg, blood, spinal fluid, bronchoalveolar fluid, bronchial lavage fluid, endotracheal aspirates), other fluids (eg, synovial, pleural, peritoneal), bone marrow, and from biopsies of internal organs and nonsterile specimens (eg, skin scrapings, nail, hair, urine, mucosal surfaces).
    • Aspergillus is a thermophilic species that grows easily on most mycologic media. The use of fungal media, such as Sabouraud agar, increases the likelihood of isolation. Fluffy white colonies appear after 36-90 hours on the agar surface.
    • Specialized media, such as Czapek-Dox and malt extract, may be required to confirm the species' identity. Agar dilution and microtiter methods have been used for susceptibility testing against azoles.
    • Definitive diagnosis sometimes is difficult, especially in patients whose invasive aspergillosis (IA) involves nonsterile sites, such as sinuses and the respiratory tract. The reason for this difficulty is that the culture sensitivity of sputum and respiratory tract secretions obtained by bronchoalveolar lavage (BAL) and bronchial washings may vary 50-60%. A positive culture result may also represent simple colonization. Nevertheless, in the appropriate clinical setting, repeated positive BAL culture findings have proven reliable evidence for diagnosis.
    • The isolation of Aspergillus from BAL fluid in patients with immunosuppression is highly indicative of invasive aspergillosis and has a specificity of 97%. For these patients, histological analysis must be combined with culture to confirm a definite diagnosis. For example, BAL culture findings may be combined with positive transbronchial biopsy specimen findings obtained at bronchoscopy.
    • Recovery of Aspergillus species from a sterile site, such as the brain (eg, brain abscess), or from the eye provides a valuable tool for definitively diagnosing invasive aspergillosis. Blood culture results are seldom positive.
  • Serology/antigen and polymerase chain reaction (PCR)
    • Although serological tests are not widely advocated to help diagnose invasive aspergillosis, these tests have a role in diagnosing aspergillosis in immunocompetent patients, including those with allergic bronchopulmonary aspergillosis (ABPA) or aspergilloma. In this group of patients, the most commonly used techniques to detect anti-Aspergillus antibodies are double immunodiffusion and counter immunoelectrophoresis. In contrast, results from these tests are unlikely to be positive in an immunocompromised host because neither can elicit a sufficient antibody response.
    • Circulating antigens in the biological fluids, such as galactomannan (GM) and 1-3-beta-glucan, have been used to help diagnose invasive aspergillosis.
    • The sandwich enzyme-linked immunosorbent assay (ELISA) test detects as much as 0.5 ng of GM per mL of serum and is currently the most sensitive method.2 This test has been recently approved by the US Food and Drug Administration (FDA) and is available for use in the United States. A meta-analysis has shown moderate accuracy in immunocompromised patients, especially for those patients with hematological malignancies or hematological transplant recipients.3
    • GM is a heat-stable heteropolysaccharide released from aspergillus hyphae during periods of active growth. The negative predictive value of the ELISA test is very good and allows the diagnosis to be made prior to clinical manifestations
    • Aquino et al have described the reasons for false-positive and false-negative results, which are the primary limitation for this test.2 False-positive results could be attributed to use of antibiotics in the pediatric population, infections caused by penicillin species, autoantibodies, contaminated swabs, bacteremia, and airway colonization by Aspergillus. The quantity of GM released can vary according to the species involved and several non-Aspergillus species can give rise to false-positive GM ELISA reactions. False-negative results could be ascribed to prior exposure to antifungal drugs or a cut-off that is too high.
    • EB-A2 rat monoclonal antibody is used in the presently available commercial ELISA testing for serum; this has detection limit of 0.5-1 ng/mL (10-15 times lower than the previously used tests).
    • GM can also be recovered from urine, cerebrospinal fluid, BAL samples but further testing is warranted to compare sensitivity and specificity prior to widespread use.
    • Animal studies performed by Francesconi et al have shown that combining GM and quantitative PCR (qPCR) may lead to a better diagnostic outcome than either alone.4 Further studies are warranted in humans though to reach similar conclusions. It could be used as a prognostic indicator; titers of GM have been shown to fall with clinical response to therapy. However, in patients receiving caspofungin, the titers may not be in concordance with response and may be paradoxically high.
    • A probable diagnosis of invasive aspergillosis can be made in a patient with profound neutropenia, radiological evidence, and 2 consecutive positive serum GM test results. Further studies are needed prior to the use of GM assay as a surveillance tool in diagnosing invasive aspergillosis. Use of PCR to detect these antigens in specimens of blood or BAL is also under investigation. One study showed high sensitivity and specificity and good agreement of PCR with the GM assay.
  • Other laboratory tests
    • A diagnosis of ABPA often requires fulfillment of the following criteria:
      • Asthma
      • Elevated total serum immunoglobulin E (IgE) level
      • Peripheral blood eosinophilia
      • Precipitating serum antibodies against A fumigatus
      • Proximal bronchiectasis
      • Immediate cutaneous reactivity to A fumigatus antigens or specific serum IgE to A fumigatus, based on radioallergosorbent test (RAST) results
    • ABPA is suggested by an unexplained exacerbation of bronchial asthma. In patients with cystic fibrosis, wheezing, failure of antibiotherapy, and changes in the radiographic findings may suggest ABPA. A possible diagnosis of ABPA may be made with the presence of asthma or eosinophilia. Fleeting pulmonary infiltrates make the diagnosis of probable ABPA, whereas central bronchiectasis makes the diagnosis almost certain. Serologic assessment consistent with ABPA includes precipitins against A fumigatus, positive IgE antibody more than 2 times asthma control, immunoglobulin G (IgG) antibody more than 2 times asthma control, and total serum IgE more than 1000 ng/mL. Diagnosis is established if all 4 serology test results are positive; 3 positive serology test results make the diagnosis very likely. A decline in the serum IgE levels by 50-75% after treatment with prednisone is consistent with the diagnosis of ABPA.
    • Allergic fungal rhinosinusitis is diagnosed by the demonstration of type 1 hypersensitivity, presence of nasal polyps, characteristic CT scan findings (central areas of hyperattenuation within the sinus cavity), positive fungal stain or culture, and allergic mucin with fungal elements and no tissue invasion.

Imaging Studies

  • Pulmonary
    • For patients with immunocompromise, perform a detailed radiographic evaluation, consisting of chest radiography and CT scans, within 24 hours after suspecting an invasive aspergillosis diagnosis.
    • Plain film chest radiography may reveal pleural-based wedge-shaped lesions and cavitations, which are characteristic of invasive pulmonary aspergillosis.
    • CT scanning is a valuable adjunct for early diagnosis of invasive aspergillosis. A characteristic early finding on CT scan is the halo sign, which consists of ground glass attenuation surrounding a soft tissue nodule. The halo sign is caused by hemorrhage around the central necrotic nodule. With cavitation of this nodule, an air crescent sign may subsequently develop. A halo sign on CT scan, combined with positive Aspergillus antigen test results, supports a diagnosis of invasive pulmonary aspergillosis.
  • Sinuses
    • Characteristic CT scan findings include unilateral involvement of several sinuses, absence of air fluid levels, and smooth thickened sinus linings.
    • MRIs of the sinuses are a useful adjunct tool for early invasive aspergillosis diagnosis. Fluid opacification of the sinuses is characteristic.
  • Cerebral: CT scans may reveal brain abscess with ring enhancement or infarction with contrast enhancement.

Procedures

  • If invasive pulmonary aspergillosis is strongly suspected in patients with diffuse disease and bilateral consolidation, bronchoscopy and bronchial biopsy can be used to help establish the diagnosis.
  • In patients with peripheral pulmonary lesions, consider a needle biopsy or surgical resection because of difficult access through bronchoscopy.
  • Perform invasive procedures with care in patients who are debilitated and neutropenic.

Histologic Findings

  • Histological section of tissues obtained by biopsy reveals a characteristic pattern that may help diagnose aspergillosis. Fungal mycelia usually have a radiating pattern with invasion of the surrounding blood vessels. Features suggestive of Aspergillus species in biopsy specimens include dichotomously branching hyphae at 45° angles, uniform mycelial width, and septate hyphae.
  • Extensive tissue necrosis with hemorrhagic infarction may be apparent at the infection site.

More on Aspergillosis

Overview: Aspergillosis
Differential Diagnoses & Workup: Aspergillosis
Treatment & Medication: Aspergillosis
Follow-up: Aspergillosis
References

References

  1. Greenberger PA, Patterson R. Diagnosis and management of allergic bronchopulmonary aspergillosis. Ann Allergy. Jun 1986;56(6):444-8. [Medline].

  2. Aquino VR, Goldani LZ, Pasqualotto AC. Update on the contribution of galactomannan for the diagnosis of invasive aspergillosis. Mycopathologia. Apr 2007;163(4):191-202. [Medline].

  3. Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis. May 15 2006;42(10):1417-727. [Medline].

  4. Francesconi A, Kasai M, Petraitiene R, et al. Characterization and comparison of galactomannan enzyme immunoassay and quantitative real-time PCR assay for detection of Aspergillus fumigatus in bronchoalveolar lavage fluid from experimental invasive pulmonary aspergillosis. J Clin Microbiol. Jul 2006;44(7):2475-80. [Medline].

  5. Abbasi S, Shenep JL, Hughes WT, Flynn PM. Aspergillosis in children with cancer: A 34-year experience. Clin Infect Dis. Nov 1999;29(5):1210-9. [Medline].

  6. Blum MD, Weidermann BL. Aspergillus infections. In: Feigin RD, Cherry JD, eds. Textbook of Pediatric Infectious Diseases. Vol 2. 5th ed. W B Saunders and Co; 2004:2288-96.

  7. Denning DW. Invasive aspergillosis. Clin Infect Dis. Apr 1998;26(4):781-803; quiz 804-5. [Medline].

  8. Dismukes WE. Antifungal therapy: lessons learned over the past 27 years. Clin Infect Dis. May 1 2006;42(9):1289-96. [Medline].

  9. Hetherington S. Etiologic agents of infectious disease. In: Long SS, Pickering LK, Prober CG, eds. Principles and Practice of Pediatric Infectious Diseases. ed. Churchill Livingstone; 1997:1326-32.

  10. Kuhlman JE, Fishman EK, Burch PA, et al. Invasive pulmonary aspergillosis in acute leukemia. The contribution of CT to early diagnosis and aggressive management. Chest. Jul 1987;92(1):95-9. [Medline].

  11. Latge JP. Aspergillus fumigatus and aspergillosis. Clin Microbiol Rev. Apr 1999;12(2):310-50. [Medline].

  12. McWhinney PH, Kibbler CC, Hamon MD, et al. Progress in the diagnosis and management of aspergillosis in bone marrow transplantation: 13 years' experience. Clin Infect Dis. Sep 1993;17(3):397-404. [Medline].

  13. Patterson TF. Aspergillus species. In: Mandell GL, Benett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. Vol 2. 6th ed. Churchill Livingstone; 2005:2958-70.

  14. Pickering LK. Aspergillosis. In: Pickering LK, ed. 2003 Red Book: Report of the Committee on Infectious Diseases. 26th ed. Elk Grove, IL: American Academy of Pediatrics; 2003:208-10,725.

  15. Segal BH, Walsh TJ. Current approaches to diagnosis and treatment of invasive aspergillosis. Am J Respir Crit Care Med. Apr 1 2006;173(7):707-17. [Medline].

  16. Steinbach WJ. Antifungal agents in children. Pediatr Clin North Am. Jun 2005;52(3):895-915, viii. [Medline].

  17. Steinbach WJ. Pediatric aspergillosis: disease and treatment differences in children. Pediatr Infect Dis J. Apr 2005;24(4):358-64. [Medline].

  18. Stevens DA, Kan VL, Judson MA, et al. Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clin Infect Dis. Apr 2000;30(4):696-709. [Medline].

  19. Walmsley S, Devi S, King S, et al. Invasive Aspergillus infections in a pediatric hospital: a ten-year review. Pediatr Infect Dis J. Aug 1993;12(8):673-82. [Medline].

  20. Walsh TJ, Hiemenz JW, Seibel NL, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis. Jun 1998;26(6):1383-96. [Medline].

  21. White PL, Linton CJ, Perry MD, et al. The evolution and evaluation of a whole blood polymerase chain reaction assay for the detection of invasive aspergillosis in hematology patients in a routine clinical setting. Clin Infect Dis. Feb 15 2006;42(4):479-86. [Medline].

  22. Zaoutis TE, Heydon K, Chu JH, et al. Epidemiology, outcomes, and costs of invasive aspergillosis in immunocompromised children in the United States, 2000. Pediatrics. Apr 2006;117(4):e711-6. [Medline].

Further Reading

Keywords

aspergillosis, Aspergillus, Aspergillus fumigatus, Aspergillus flavus, allergic bronchopulmonary aspergillosis, ABPA, aspergilloma, invasive aspergillosis, IA, noninvasive aspergillosis, Aspergillus niger, Aspergillus terreus, Aspergillus amstelodami, Aspergillus avenaceus, Aspergillus caesiellus, Aspergillus carneus, Aspergillus clavatus, Aspergillus oryzae, Aspergillus versicolor, Aspergillus wentii, allergic sinusitis, asthma, alveolitis, cellulitis, pneumonia, esophagitis, cystic fibrosis, CF, tuberculosis, sarcoidosis, bone marrow transplantation, graft versus host disease, graft rejection, hematopoietic stem cell transplantation, HSCT, heart and lung transplantation, chronic granulomatous disease, leukemia, diabetes mellitus, respiratory failure

Contributor Information and Disclosures

Author

Vandana Batra, MD, Pediatrician, Department of Pediatrics, Division of General Pediatrics/Primary Care, Nemours Pediatrics
Vandana Batra, MD is a member of the following medical societies: American Academy of Pediatrics
Disclosure: Nothing to disclose.

Coauthor(s)

Basim Asmar, MD, Director, Department of Pediatrics, Division of Infectious Diseases, Children's Hospital of Michigan; Professor, Department of Pediatrics, Wayne State University School of Medicine
Basim Asmar, MD is a member of the following medical societies: American Academy of Pediatrics, American Society for Microbiology, Infectious Diseases Society of America, and Pediatric Infectious Diseases Society
Disclosure: Nothing to disclose.

Jocelyn Y Ang, MD, Assistant Professor, Department of Pediatrics, Division of Infectious Diseases, Children's Hospital of Michigan and Wayne State University
Jocelyn Y Ang, MD is a member of the following medical societies: American Academy of Pediatrics, Infectious Diseases Society of America, and Pediatric Infectious Diseases Society
Disclosure: Nothing to disclose.

Medical Editor

Itzhak Brook, MD, MSc, Professor, Department of Pediatrics, Georgetown University School of Medicine
Itzhak Brook, MD, MSc is a member of the following medical societies: American Association for the Advancement of Science, American College of Physicians-American Society of Internal Medicine, American Federation for Clinical Research, American Medical Association, American Society for Microbiology, Armed Forces Infectious Diseases Society, Association of Military Surgeons of the US, Infectious Diseases Society of America, International Immunocompromised Host Society, International Society for Infectious Diseases, Medical Society of the District of Columbia, New York Academy of Sciences, Pediatric Infectious Diseases Society, Society for Ear, Nose and Throat Advances in Children, Society for Experimental Biology and Medicine, Society for Pediatric Research, Southern Medical Association, and Surgical Infection Society
Disclosure: Nothing to disclose.

Pharmacy Editor

Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine
Disclosure: Pfizer Inc Stock Investment from broker recommendation; Avanir Pharma Stock Investment from broker recommendation

Managing Editor

Mark R Schleiss, MD, American Legion Chair of Pediatrics, Professor of Pediatrics, Division Director, Division of Infectious Diseases and Immunology, Department of Pediatrics, University of Minnesota School of Medicine
Mark R Schleiss, MD is a member of the following medical societies: American Pediatric Society, Infectious Diseases Society of America, Pediatric Infectious Diseases Society, and Society for Pediatric Research
Disclosure: Nothing to disclose.

CME Editor

Robert W Tolan Jr, MD, Chief, Division of Allergy, Immunology and Infectious Diseases, The Children's Hospital at Saint Peter's University Hospital; Clinical Associate Professor of Pediatrics, Drexel University College of Medicine
Robert W Tolan Jr, MD is a member of the following medical societies: American Academy of Pediatrics, American Medical Association, American Society for Microbiology, American Society of Tropical Medicine and Hygiene, Infectious Diseases Society of America, Pediatric Infectious Diseases Society, Phi Beta Kappa, and Physicians for Social Responsibility
Disclosure: GlaxoSmithKline Honoraria Speaking and teaching; MedImmune Honoraria Consulting; MedImmune Honoraria Speaking and teaching; Merck Honoraria Speaking and teaching; Novartis Honoraria Speaking and teaching; sanofi pasteur Grant/research funds Unrestricted research grant; sanofi pasteur  Consulting; sanofi pasteur Honoraria Speaking and teaching; Tap Honoraria Speaking and teaching

Chief Editor

Russell W Steele, MD, Head, Division of Pediatric Infectious Diseases, Ochsner Children's Health Center; Clinical Professor, Department of Pediatrics, Tulane University School of Medicine
Russell W Steele, MD is a member of the following medical societies: American Academy of Pediatrics, American Association of Immunologists, American Pediatric Society, American Society for Microbiology, Infectious Diseases Society of America, Louisiana State Medical Society, Pediatric Infectious Diseases Society, Society for Pediatric Research, and Southern Medical Association
Disclosure: None None None

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.